Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H021 enteric-coated tablets in moderate-to-severe active ulcerative colitis
CTR20260232Phase 2Active
- Sponsor
- 江苏柯菲平医药股份有限公司
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of H021 in autoimmune colitis, sponsored by 江苏柯菲平医药股份有限公司. Started May 2026; status: active.
02
Drugs
H021
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20260232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260232.